<h2>Clinical Framing of Substance Use Emergencies</h2>
<p>Substance abuse and substance use disorders (SUDs) represent a significant portion of psychiatric emergencies encountered in the emergency department (ED). Patients may present with acute intoxication, life-threatening withdrawal syndromes, complications of chronic use, or trauma related to substance use. The emergency nurse must rapidly differentiate between medical emergencies (e.g., overdose, metabolic derangement) and psychiatric presentations, often managing both simultaneously.<sup><a href="#ref-5">[5]</a></sup></p>
<p>For the CEN exam, mastery of this topic requires a dual focus: recognizing specific toxidromes and withdrawal syndromes, and applying evidence-based pharmacological and safety interventions. The Joint Commission and the CDC emphasize screening, brief intervention, and referral to treatment (SBIRT), making this a high-yield clinical and exam priority.<sup><a href="#ref-8">[8]</a></sup></p>
<h2>Essential Terminology and Substance Categories</h2>
<h3>Essential Terminology</h3>
<ul>
<li><strong>Tolerance:</strong> A state of adaptation in which exposure to a drug induces changes that result in a diminution of one or more of the drug’s effects over time.</li>
<li><strong>Withdrawal:</strong> A syndrome resulting from the abrupt cessation or reduction of a substance that has been used heavily and long-term. Withdrawal syndromes are often opposite to the effects of the substance.</li>
<li><strong>Intoxication (Overdose):</strong> A reversible, substance-specific syndrome caused by recent ingestion of or exposure to a substance. It involves maladaptive behavioral or psychological changes (e.g., coma, respiratory depression, agitation).</li>
<li><strong>Polypharmacy / Polysubstance Use:</strong> Using multiple substances simultaneously. This is a common ED presentation and greatly complicates the clinical picture, as toxidromes may blend (e.g., opioid OD with stimulant-induced agitation).<sup><a href="#ref-9">[9]</a></sup></li>
</ul>
<h3>Common Substances of Abuse (High-Yield Categories)</h3>
<table>
<thead>
<tr>
<th>Category</th>
<th>Examples</th>
<th>Mechanism of Action (Simplified)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CNS Depressants</strong></td>
<td>Alcohol (ETOH), Benzodiazepines, Barbiturates</td>
<td>Enhance GABA activity. Cross-tolerance is common.</td>
</tr>
<tr>
<td><strong>Opioids</strong></td>
<td>Heroin, Morphine, Oxycodone, Fentanyl</td>
<td>Bind to mu-opioid receptors, causing analgesia, euphoria, and respiratory depression.</td>
</tr>
<tr>
<td><strong>CNS Stimulants</strong></td>
<td>Cocaine, Methamphetamine, MDMA</td>
<td>Increase dopamine/norepinephrine. Leads to hypertension, tachycardia, and hyperthermia.</td>
</tr>
<tr>
<td><strong>Hallucinogens / Dissociatives</strong></td>
<td>LSD, Psilocybin, PCP, Ketamine</td>
<td>Alter perception, cognition, and sensorium via serotonin/NMDA receptors.</td>
</tr>
</tbody>
</table>
<h2>Differentiating Intoxication and Withdrawal Syndromes</h2>
<h3>Intoxication (Overdose) Management</h3>
<p>The emergency nurse's primary goal is stabilizing the "ABCs" while identifying the toxic agent. This often requires a high index of suspicion due to unreliable patient histories.</p>
<ol>
<li><strong>A – Airway:</strong> Gag reflex may be absent (opioids, depressants). Prepare for intubation. Protect airway in any patient with a GCS < 8.</li>
<li><strong>B – Breathing:</strong> Hypoventilation is classic for opioids and depressants. Apply supplemental oxygen and assist ventilations with a bag-valve-mask if needed.</li>
<li><strong>C – Circulation:</strong> Cardiac monitoring is essential. Cocaine can cause lethal dysrhythmias; Alcohol/Depressants cause hypotension. Obtain IV access.</li>
<li><strong>D – Disability (Neurologic):</strong> Quick bedside neurological exam. Check pupil size (miosis = opioids; mydriasis = stimulants/withdrawal). Check glucose to rule out hypoglycemia.</li>
<li><strong>E – Exposure:</strong> Undress to assess for trauma, track marks, hyperthermia, or infection (endocarditis, abscesses).<sup><a href="#ref-1">[1]</a></sup></li>
</ol>
<h3>Withdrawal Syndromes</h3>
<p>Withdrawal from CNS depressants (alcohol, benzodiazepines) is the most dangerous and potentially fatal withdrawal syndrome in the ED due to the risk of <strong>seizures</strong> and <strong>delirium tremens (DTs)</strong>.<sup><a href="#ref-2">[2]</a></sup></p>
<ul>
<li><strong>Alcohol Withdrawal:</strong> Onset 6-24 hours. Symptoms: Tremor, diaphoresis, anxiety, nausea/vomiting, hypertension, tachycardia, hallucinations (visual/tactile), generalized tonic-clonic seizures.
<ul>
<li><strong>DTs:</strong> Onset 48-96 hours (or later). A medical emergency with severe confusion, autonomic hyperactivity (fever, severe tachycardia), and high mortality if untreated (~5-15%). Requires ICU-level care and high-dose benzodiazepines.</li>
</ul>
</li>
<li><strong>Opioid Withdrawal:</strong> Onset 6-12 hours (short-acting opioids). Uncomfortable but rarely life-threatening. Symptoms: Yawning, rhinorrhea, piloerection ("cold turkey"), mydriasis, abdominal cramping, diarrhea, nausea, vomiting, bone/muscle aches, anxiety.</li>
<li><strong>Stimulant Withdrawal ("Crash"):</strong> Fatigue, depression, hypersomnia, psychomotor retardation. Risk of suicide is elevated during this phase.</li>
</ul>
<h2>Clinical Screening Tools and Withdrawal Scales</h2>
<h3>Validated Screening Tools (High Yield for CEN)</h3>
<p><strong>CAGE Questionnaire:</strong> Used for rapid screening of alcohol use disorder. Remember the mnemonic:<br>
<strong>C</strong> – Have you ever felt you should <strong>C</strong>ut down on your drinking?<br>
<strong>A</strong> – Have people <strong>A</strong>nnoyed you by criticizing your drinking?<br>
<strong>G</strong> – Have you ever felt <strong>G</strong>uilty about your drinking?<br>
<strong>E</strong> – Have you ever had a drink first thing in the morning (<strong>E</strong>ye-opener)?<br>
A score of ≥ 2 is considered clinically significant.<sup><a href="#ref-4">[4]</a></sup></p>
<p><strong>Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar):</strong> A symptom-triggered assessment tool for alcohol withdrawal monitoring. It tracks symptoms like nausea, tremor, anxiety, and agitation. A score of:
<ul>
<li>0–9: Minimal withdrawal</li>
<li>10–19: Moderate withdrawal</li>
<li>≥ 20: Severe withdrawal (high risk for DTs)<sup><a href="#ref-6">[6]</a></sup></li>
</ul></p>
<p><strong>Clinical Opiate Withdrawal Scale (COWS):</strong> Used to assess the severity of opioid withdrawal and determine eligibility for buprenorphine induction. Includes pulse rate, sweating, restlessness, pupil size, and GI upset. A score of 13–24 is moderate withdrawal; 25–36 is moderately severe.<sup><a href="#ref-7">[7]</a></sup></p>
<h2>Pharmacologic Management and Safety Interventions</h2>
<h3>Pharmacological Interventions</h3>
<ul>
<li><strong>Alcohol Withdrawal (The Gold Standard): <em>Benzodiazepines</em></strong>
<ul>
<li>Long-acting: <strong>Diazepam (Valium)</strong> or <strong>Chlordiazepoxide (Librium)</strong> – preferred for severe withdrawal due to self-tapering effect.</li>
<li>High-potency: <strong>Lorazepam (Ativan)</strong> – preferred in elderly, hepatic impairment, or for acute seizures.</li>
<li><strong>Thiamine (100 mg IV/IM):</strong> Administer <strong>before</strong> any glucose containing fluids to prevent or treat Wernicke encephalopathy.</li>
</ul>
</li>
<li><strong>Opioid Overdose:</strong>
<ul>
<li><strong>Naloxone (Narcan):</strong> Administer IV/IM/IN. Titrate to respiratory rate of 12-16 and adequate tidal volume, while avoiding acute withdrawal. Onset 1-2 min IV, 3-5 min IM/IN. Duration is shorter than many opioids (especially fentanyl); <strong>repeat doses or continuous infusion</strong> may be required.<sup><a href="#ref-1">[1]</a></sup></li>
</ul>
</li>
<li><strong>Opioid Withdrawal:</strong>
<ul>
<li><strong>Buprenorphine (Suboxone):</strong> Partial mu-agonist. Indicated for moderate-to-severe withdrawal (COWS > 13). Must be administered <strong>after</strong> objective withdrawal is evident to avoid precipitating withdrawal.</li>
<li><strong>Methadone:</strong> Full mu-agonist. Used in regulated detoxification settings.</li>
<li><strong>Clonidine:</strong> Alpha-2 agonist. Reduces sympathetic outflow (sweating, tremors, hypertension, anxiety).</li>
</ul>
</li>
<li><strong>Stimulant (Cocaine/Methamphetamine) Intoxication:</strong>
<ul>
<li><strong>Agitation/Sympathomimetic Toxicity:</strong> <strong>Benzodiazepines</strong> (Lorazepam/Diazepam) are first-line for agitation, hypertension, and tachycardia.</li>
<li>Avoid beta-blockers (may cause unopposed alpha stimulation leading to hypertensive crisis).</li>
<li><strong>Aggressive cooling</strong> for hyperthermia if needed (ice packs, cooled IV fluids).</li>
</ul>
</li>
</ul>
<h3>Patient Safety and De-escalation</h3>
<ul>
<li>Place the patient in a quiet, low-stimulus environment to reduce agitation.</li>
<li>Maintain a calm, non-judgmental, and therapeutic approach. Use "active listening" and offer choices to give the patient a sense of control.</li>
<li>If pharmacologic restraint is needed for severe agitation (vs. physical restraint), <strong>parenteral benzodiazepines</strong> or <strong>antipsychotics</strong> (e.g., Haloperidol IM) are used. Monitor for QT prolongation with antipsychotics.</li>
</ul>
<h2>Life-Threatening Complications and Medication Traps</h2>
<ul>
<li><strong>Wernicke-Korsakoff Syndrome:</strong> A neuropsychiatric emergency caused by thiamine deficiency, commonly in chronic alcohol users.
<ul>
<li><strong>Wernicke Encephalopathy (Acute):</strong> Triad of <strong>C</strong>onfusion, <strong>A</strong>taxia, <strong>O</strong>phthalmoplegia (nystagmus). Requires emergent thiamine replacement. Give Thiamine 100 mg IV <strong>BEFORE</strong> glucose!</li>
<li><strong>Korsakoff Psychosis (Chronic):</strong> Amnesia, confabulation, apathy. Usually irreversible.<sup><a href="#ref-10">[10]</a></sup></li>
</ul>
</li>
<li><strong>Respiratory Depression:</strong> Opioids and benzodiazepines cause respiratory depression. Have naloxone, airway equipment, and BVM ready.</li>
<li><strong>Polypharmacy Overdose (Acetaminophen + Opioids):</strong> Many combination medications (e.g., Vicodin, Percocet) contain acetaminophen. The CEN exam often tests the need to check an <strong>acetaminophen level</strong> in any oral opioid overdose, and treat with <strong>N-acetylcysteine (NAC/Mucomyst)</strong> if indicated.</li>
<li><strong>Flumazenil (Romazicon) is CONTRAINDICATED in routine benzodiazepine overdose</strong> in the ED, especially in patients with chronic benzodiazepine use or unknown ingestion (e.g., co-ingestion of TCA). It can precipitate refractory seizures. This is a classic CEN exam trap!<sup><a href="#ref-5">[5]</a></sup></li>
</ul>
<h2>Essential Differentiators and Safety Priorities for the CEN Exam</h2>
<ul>
<li><strong>Know the Toxidromes:</strong> The single most important skill for the exam.
<ul>
<li><strong>Opioid OD:</strong> <strong>Respiratory depression</strong> + Pinpoint pupils + Coma.</li>
<li><strong>Alcohol Withdrawal:</strong> <strong>Tachycardia/Hypertension</strong> + Tremor + Hallucinations + Seizures.</li>
<li><strong>Sympathomimetic OD (Cocaine):</strong> <strong>Hypertension</strong> + Tachycardia + Hyperthermia + Agitation.</li>
</ul>
</li>
<li><strong>Contrast OD vs. Withdrawal:</strong>
<ul>
<li>OD = Depressed vitals (low RR, low HR, low BP).</li>
<li>Withdrawal = Elevated vitals (high HR, high BP, high temp).</li>
</ul>
</li>
<li><strong>CIWA-Ar vs. COWS:</strong> CIWA-Ar is for alcohol (Benzos are treatment). COWS is for opioids (Buprenorphine is treatment). They are NOT interchangeable.</li>
<li><strong>Thiamine before Glucose:</strong> This is a high-yield patient safety priority for any at-risk patient with altered mental status to prevent iatrogenic Wernicke encephalopathy.</li>
<li><strong>Safety over Everything:</strong> The emergency nurse must monitor for withdrawal progression, protect the airway, and use restraints only as a last resort, applying them safely and legally.<sup><a href="#ref-4">[4]</a></sup></li>
</ul>
<h2>References & Sources</h2>
<ol>
<li id="ref-1">Panchal, A. R., Bartos, J. A., Cabañas, J. G., et al. (2020). Part 3: Adult Basic and Advanced Life Support: 2020 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. <em>Circulation</em>, 142(16_suppl_2), S366–S468. <a href="https://doi.org/10.1161/CIR.0000000000000916" target="_blank">https://doi.org/10.1161/CIR.0000000000000916</a></li>
<li id="ref-2">American Psychiatric Association. (2018). <em>Practice Guideline for the Pharmacological Treatment of Patients With Alcohol Use Disorder</em>. American Psychiatric Publishing. <a href="https://pubmed.ncbi.nlm.nih.gov/29301420/" target="_blank">https://doi.org/10.1176/appi.books.9780890425796</a></li>
<li id="ref-3">World Health Organization. (2021). <em>Clinical Guidelines for Withdrawal Management and Treatment of Drug Dependence in Closed Settings</em>. WHO Press. <a href="https://www.ncbi.nlm.nih.gov/books/NBK310654/" target="_blank">https://www.who.int/publications/i/item/9789290612695</a></li>
<li id="ref-4">Saunders, A. N. (2021). <em>Saunders Comprehensive Review for the CEN Examination</em> (2nd ed.). Elsevier. <a href="https://evolve.elsevier.com/cs/product/9780323830317" target="_blank">https://www.elsevier.com/books/saunders-comprehensive-review-for-the-cen-examination/9780323672845</a></li>
<li id="ref-5">Emergency Nurses Association. (2020). <em>Sheehy's Emergency Nursing: Principles and Practice</em> (7th ed.). Mosby/Elsevier. <a href="https://evolve.elsevier.com/cs/product/9780323485463" target="_blank">https://www.ena.org/store/books/sheehys-emergency-nursing-principles-and-practice</a></li>
<li id="ref-6">Sullivan, J. T., Sykora, K., Schneiderman, J., Naranjo, C. A., & Sellers, E. M. (1989). Assessment of alcohol withdrawal: the revised clinical institute withdrawal assessment for alcohol scale (CIWA-Ar). <em>British Journal of Addiction</em>, 84(11), 1353–1357. <a href="https://pubmed.ncbi.nlm.nih.gov/2788174/" target="_blank">https://pubmed.ncbi.nlm.nih.gov/2788174/</a></li>
<li id="ref-7">Wesson, D. R., & Ling, W. (2003). The Clinical Opiate Withdrawal Scale (COWS). <em>Journal of Psychoactive Drugs</em>, 35(2), 253–259. <a href="https://pubmed.ncbi.nlm.nih.gov/12826998/" target="_blank">https://pubmed.ncbi.nlm.nih.gov/12826998/</a></li>
<li id="ref-8">Dowell, D., Haegerich, T. M., & Chou, R. (2016). CDC Guideline for Prescribing Opioids for Chronic Pain — United States, 2016. <em>Morbidity and Mortality Weekly Report (MMWR)</em>, 65(1), 1–49. <a href="https://doi.org/10.15585/mmwr.rr6501e1" target="_blank">https://doi.org/10.15585/mmwr.rr6501e1</a></li>
<li id="ref-9">National Institute on Drug Abuse. (2020). <em>Principles of Drug Addiction Treatment: A Research-Based Guide</em> (3rd ed.). National Institutes of Health. <a href="https://nida.nih.gov/sites/default/files/podat-3rdEd-508.pdf" target="_blank">https://nida.nih.gov/publications/principles-drug-addiction-treatment-research-based-guide-third-edition</a></li>
<li id="ref-10">Sechi, G., & Serra, A. (2007). Wernicke's encephalopathy: new clinical settings and recent advances in diagnosis and management. <em>The Lancet Neurology</em>, 6(5), 442–455. <a href="https://pubmed.ncbi.nlm.nih.gov/17434099/" target="_blank">https://pubmed.ncbi.nlm.nih.gov/17434099/</a></li>
</ol>